Johnson & Johnson (JNJ) classifies its product portfolio into three business segments: Pharmaceuticals, Consumer Health, and Medical Devices. Johnson & Johnson reported growth across all three segments and reported revenues of ~$20.2 billion, representing ~11.5% growth compared to its 4Q16 revenues.
The chart above compares the quarterly revenues for each business segment in 2017.
Segment-wise revenues of JNJ segments
JNJ’s Pharmaceuticals segment reported 17.6% growth in revenues to ~$9.7 billion in 4Q17, compared to ~$8.2 billion in 4Q16. This growth was driven by strong performance of Concerta, Edurant, Darzalex, Imbruvica, Stelara, Simponi/Simponi Aria, Xarelto, Zytiga, and its pulmonary hypertension products.
The Consumer segment reported 3.1% growth in revenues to ~$3.5 billion in 4Q17, compared to ~$3.4 billion in 4Q16. The growth was driven by the strong performance of its beauty care products, wound care products, and over-the-counter products. This growth was partially offset by lower sales of baby care products, oral health products, and women’s health products.
JNJ’s Medical Devices segment reported 8.3% growth in revenues to ~$7.0 billion in 4Q17, compared to $6.4 billion in 4Q16. This growth was driven by the strong performance of its cardiovascular products; hips, knees, and trauma products; general and advanced surgery products; and contact lenses.
Excluding the impact of acquisitions and divestitures, the Pharmaceutical segment reported growth of ~7.6% in worldwide sales, and the Consumer segment reported growth of ~0.2% in worldwide sales. The company’s Medical Devices segment reported growth of ~2.0% in worldwide sales.
The Vanguard Dividend Appreciation ETF (VIG) holds 12.5% of its total investments in healthcare companies. VIG holds 3.7% in Johnson & Johnson (JNJ), 2.8% in Medtronic (MDT), 2.6% in Abbott Laboratories (ABT), and 1.5% in Stryker (SYK).